Kolon Pharma Signs Exclusive Domestic Contract for Spanish Athlete's Foot Treatment 'Terbinafine Nail Lacquer'

[Asia Economy Reporter Lee Gwanju] Kolon Pharmaceutical announced on the 2nd that it has signed an exclusive domestic sales contract with Spanish pharmaceutical company Almirall for the 'Terbinafine Nail Lacquer,' a treatment for hand and toenail fungal infections.

Under this contract, Kolon Pharmaceutical will import finished products from Almirall and exclusively distribute and sell them domestically. Terbinafine is known to be the most effective oral treatment for hand and toenail fungal infections.

Using an integrated brush attached to the container cap, patients can use it conveniently and intuitively. Through proprietary know-how, the permeability through the nails has been increased while ensuring the medication remains on the nails for a long time. After applying once daily during the first month, it only needs to be applied once a week, enhancing ease of use. Terbinafine Nail Lacquer is currently approved and sold in a total of 19 countries, mainly in European countries such as Germany, Italy, and Spain.

Yeom Seunghwan, Head of Development at Kolon Pharmaceutical, said, “Through this contract, we are able to introduce a topical treatment for hand and toenail fungal infections that has excellent clinical efficacy and can be used safely for a long period in Korea. We expect to provide a treatment option that greatly increases patient convenience in terms of usage method and duration.” Kolon Pharmaceutical aims to launch the product in the first half of 2024 and grow it as one of its key dermatology products.

This content was produced with the assistance of AI translation services.